Core Viewpoint - The National Medical Products Administration (NMPA) has accepted the marketing authorization application for iza-bren, a first-in-class EGFR x HER3 bispecific antibody-drug conjugate developed by Bai Li Tian Heng, marking a significant milestone in the field of targeted therapies [1] Group 1: Company Developments - Bai Li Tian Heng has developed the world's first EGFR x HER3 bispecific antibody-drug conjugate, indicating a pioneering advancement in cancer treatment [1] - The acceptance of the marketing authorization application for iza-bren represents its first indication application successfully accepted by the NMPA [1] Group 2: Industry Implications - The acceptance of the application for iza-bren is a notable event as it is the first new drug application for a targeted EGFR x HER3 bispecific antibody-drug conjugate globally [1]